| +0.025 / +1.09%|
The 4 analysts offering 12-month price forecasts for Amicus Therapeutics Inc have a median target of 3.75, with a high estimate of 6.00 and a low estimate of 2.50. The median estimate represents a +61.29% increase from the last price of 2.33.
The current consensus among 5 polled investment analysts is to Hold stock in Amicus Therapeutics Inc. This rating has held steady since November, when it was downgraded from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.